Patient Prefer Adherence. 2013 Oct 17;7:1061-6. doi: 10.2147/PPA.S52498. eCollection 2013.
Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer.
Patient preference and adherence
Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li
Affiliations
Affiliations
- Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People's Republic of China.
PMID: 24204125
PMCID: PMC3804534 DOI: 10.2147/PPA.S52498
Abstract
PURPOSE: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients.
PATIENTS AND METHODS: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach's α coefficient, Pearson correlation test, multitrait scaling analysis, and Mann-Whitney U test.
RESULTS: Scale reliability was confirmed by Cronbach's α coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages.
CONCLUSION: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People's Republic of China.
Keywords: EORTC QLQ-CX24; People’s Republic of China; cervical cancer; quality of life
References
- Gynecol Oncol. 2010 Jan;116(1):82-7 - PubMed
- Zhonghua Fu Chan Ke Za Zhi. 2003 Nov;38(11):689-93 - PubMed
- Oncology. 2009;76(3):190-8 - PubMed
- Int J Gynecol Cancer. 2010 Jul;20(5):905-9 - PubMed
- Cancer. 2006 Oct 15;107(8):1812-22 - PubMed
- Int J Gynecol Cancer. 2010 May;20(4):664-84 - PubMed
- Int J Gynaecol Obstet. 2009 May;105(2):103-4 - PubMed
- Eur J Cancer. 2012 Nov;48(16):3009-18 - PubMed
- Psychooncology. 2008 Oct;17(10):1053-7 - PubMed
- Health Qual Life Outcomes. 2012 Oct 03;10:124 - PubMed
- Chest. 1998 Feb;113(2):467-81 - PubMed
Publication Types